Atlas Pulse News

What changed, with source links.

Atlas Pulse monitors peptide research, safety, FDA guidance, and regulatory changes. Open a card for a plain-English read, then use the original source before changing your view.

See What Changed Add updates to Watchlist

Clinical TrialClinicalTrials.govMay 29, 2026

SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.

Researchers are investigating the combination of Shingrix and a GLP-1 agonist as a potential treatment to preserve beta cells in individuals with recent-onset Type 1 Diabetes.

GLP-1

Related to peptides:

8/10

Read source